Despite widespread use, this population is underrepresented in clinical trials, creating a knowledge gap around long-term safety and optimal use
Real-world data from the LEADER cardiovascular outcomes trial (N=9,340, liraglutide 1.8 mg) showed a 22% relative reduction in a composite renal endpoint (new-onset persistent macroalbuminuria, persistent doubling of serum creatinine, end-stage renal disease, or renal death) versus placebo 6
GLP-1 Medications The Confidence Connection: Compounded GLP-1 medications like semaglutide and tirzepatide can help you regain control over your appetite, supporting your weight loss goals when combined with lifestyle modifications and medical supervision
Given the significant liability involved, obtaining thorough and appropriate medical clearance is essential
Postural strategies help manage orthostatic symptoms